24 May 2026
In plain English
Saturday edition. All seven tracked forecasts hold — a genuinely quiet day. The FDA's peptide advisory panel meets in 60 days; all six empty committee seats remain unfilled after twenty weeks. Hims & Hers (the telehealth company expected to launch a peptide product line this year) has said nothing about timing thirteen days after reporting a $92 million quarterly loss. The Medicare weight-loss drug program has 38 days until its July 1 launch with no final operational guidance published. In the background, the estrogen-patch shortage driving women to telehealth hormone providers keeps worsening — one platform reports patch sales up 150% since the FDA removed its longstanding safety warning in November. HRT prescriptions have roughly doubled since 2023. That demand surge validates The Compound's decision to ship HRT Picks twelve days ago.
Signal detail
60 days to PCAC. Historian: vacancy-absence at 20+ weeks enters rare territory for a committee Kennedy publicly committed to filling — but the base rate for batch advisory appointments is lumpy, not linear. His ACIP appointments took one burst on Feb 27 after weeks of silence. The pattern may repeat at T-30. Skeptic: quorum risk — 4 of 12 seated, no chair — remains dual-direction. A PCAC without quorum cannot issue a recommendation, resolving the forecast TRUE by default. Bayesian: prior 0.55, posterior 0.55. No new evidence.
Same institutional dynamics. No USP monograph progress for any of four tracked peptides (BPC-157, KPV, MOTS-c, TB-500). Oral presentation deadline June 30 is the next signal-rich window — industry coalition filings will reveal depth of organized support.
13 days post-Q1 earnings, no peptide launch announcement. Historian: California facility month 16 post-acquisition; 18–24 month M&A-to-launch base rate remains the anchor. Skeptic: silence is increasingly consistent with post-PCAC timing — Hims waits for regulatory cover before committing launch resources to a legally ambiguous product. Q1 net loss $92.1M and parallel diagnostics + Canada expansion distribute capital. Bayesian: no new evidence. Posterior 0.84. Augur: Hims silence while peptide search volume exceeds Ozempic creates a widening gap between consumer demand pull and corporate supply. This gap closes either via launch or via a competitor moving first.
No new adverse events. No new top-5 outlet features. Historian: 775+ adverse event reports for compounded GLP-1s (semaglutide 455+, tirzepatide 320+) provide a reference corpus — but these are GLP-1 adverse events not peptide-specific. Transfer to compounded peptides requires a named-victim event. Skeptic: FDA confirms no adverse event spike from compounded peptides specifically. Cat 1 reclassification could channel demand from gray-market to regulated pharmacies, reducing incident probability. Bayesian: dual-direction signals cancel. Posterior 0.70.
38 days to July 1. CMS operational silence at T-38 — spring 2026 guidance still undelivered. Historian: Medicare programs that don't publish operational guidance by T-30 tend to have rougher first-quarter enrollment. Window narrowing. Bayesian: no new enrollment data. Structural friction ($50 copay not toward OOP cap, prior auth, narrow drug list) unchanged. Posterior 0.72.
No new peptide DTC affiliate programs. First-party data: $0 payout, 0 conversions, third consecutive week. GLP-1 CPA dominance ($260 vs $8–40) structural. Forecast holds trivially when both numerator and denominator are near zero.
compound-peptide-property-live: holds 0.85, flagged. Ninth consecutive day flagged for formal resolution. Per operator clarification 2026-05-15, the broader portfolio-ship thesis is satisfied (HRT Picks, glp1pets, Titrate iOS, /numbers page all live). Recommend operator resolve TRUE and retire from daily re-evaluation.
How Barque got smarter today
- HRT demand signal is the strongest Ring 1 validation this week. Estrogen patch shortage + doubled prescriptions + 150% telehealth sales increase confirm the opportunity that motivated HRT Picks. This is the first time we can point to quantified demand acceleration (not just a supply crisis) as post-hoc validation of a Barque-informed build decision. Pattern: supply shortage → telehealth channel expansion → comparison-site demand. Reusable for future Ring 1 builds.
- Resolution fatigue is a protocol gap. compound-peptide-property-live has been flagged for 9 consecutive days without operator resolution. The protocol assumes responsive operators; when the operator is building products (which is the whole point), resolution backlogs accumulate. Consider: auto-archive forecasts after 14 days of continuous resolution-flagging, with a final prominent callout in that day's brief.
- Firehose silence persists: day 3. Zero overnight captures in a week with TRIUMPH-1 coverage and HRT shortage news. Likely a listener health issue, not a genuinely silent news cycle. Operational priority.
- Sources sampled. Tier 1: FDA.gov (PCAC roster, advisory calendar), CMS.gov (Bridge page), FiercePharma (oral GLP-1 tracker), SEC EDGAR (Akston filings), AJMC, NPR, NBC News. Tier 2 (rotated): PeptideDeck, RemyPeptides, BSR Intelligence, CNN (HRT shortage), 19th News. Tier 3: TechTimes (retatrutide cultural framing), PolicyLab (HRT patch online access). First-party: Katalys + GSC (May 23 aggregation).